Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846495 · ClinicalTrials.gov registry record · Phase 4
Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine
A Phase 4 study, sponsored by Clinvest.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
NCT00846495: Completed Phase 4 study, sponsored by Clinvest.
NCT00846495 is a Phase 4 study that has completed, run by Clinvest. The registered enrollment target is 55 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00846495, a Phase 4 study, has completed, sponsored by Clinvest.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
Study Summary
Subjects enrolled at 2 investigative sites will complete 3 visits. Following Visit 1, during a 1-month Baseline Period, subjects will treat with their usual medication and document any warning signs (Prodrome pre-headache) that a migraine will occur. Following randomization (like a flip of the coin) at Visit 2, subjects will treat daily with topiramate or during Prodrome with frovatriptan. Subjects complete a 2-month Treatment Period before exit at Visit 3.This study will compare the effectiveness of daily treatment vs. treatment during the pre-headache phase for prevention of migraine.
Primary Outcome
Compare number of migraine attacks reported by participants using frovatriptan in a preemptive treatment paradigm vs. daily topiramate during Treatment Period Month 2
Interventions
- DRUG topiramate
- DRUG frovatriptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
What the finished NCT00846495 record still lists
NCT00846495 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which topiramate is the first listed.
NCT00846495 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00846495 about?
NCT00846495 is a clinical study titled "Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine". Subjects enrolled at 2 investigative sites will complete 3 visits. Following Visit 1, during a 1-month Baseline Period, subjects will treat with their usual medication and document any warning signs (Prodrome pre-headache) that a migraine will occur. Following randomization (like a flip of the coin)...
What is the current status of trial NCT00846495?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2009-08. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00846495?
The interventions under investigation include: topiramate (DRUG), frovatriptan (DRUG).
Who is sponsoring clinical trial NCT00846495?
This trial is sponsored by Clinvest, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00846495's enrollment target sits among peer trials
55 1218th of 2000 higher than 778 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia